233 related articles for article (PubMed ID: 7515925)
1. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
2. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
3. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
Praz F; Lesavre P
J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
Seya T; Hara T; Matsumoto M; Akedo H
J Immunol; 1990 Jul; 145(1):238-45. PubMed ID: 1694203
[TBL] [Abstract][Full Text] [Related]
5. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
6. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
[TBL] [Abstract][Full Text] [Related]
7. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
Matsumoto M; Sugita Y; Seya T
Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
[TBL] [Abstract][Full Text] [Related]
8. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
[TBL] [Abstract][Full Text] [Related]
9. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
[TBL] [Abstract][Full Text] [Related]
10. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
11. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface.
Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T
Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318
[TBL] [Abstract][Full Text] [Related]
12. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
[TBL] [Abstract][Full Text] [Related]
13. Complement-activating ability of leucocytes from patients with complement factor I deficiency.
Marquart HV; Rasmussen JM; Leslie RG
Immunology; 1997 Jul; 91(3):486-92. PubMed ID: 9301541
[TBL] [Abstract][Full Text] [Related]
14. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
Olesen EH; Johnson AA; Damgaard G; Leslie RG
Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
[TBL] [Abstract][Full Text] [Related]
15. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
16. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
[TBL] [Abstract][Full Text] [Related]
17. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
Leslie RG; Prodinger WM; Nielsen CH
Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
[TBL] [Abstract][Full Text] [Related]
18. Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures.
Döpper S; Wilflingseder D; Prodinger WM; Stiegler G; Speth C; Dierich MP; Stoiber H
Eur J Immunol; 2003 Aug; 33(8):2098-107. PubMed ID: 12884283
[TBL] [Abstract][Full Text] [Related]
19. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
[TBL] [Abstract][Full Text] [Related]
20. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
